We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
The Therapeutic Goods Administration (TGA) has issued 5 infringement notices totalling $66,600 to Affinity Corp Australia Pty Ltd for the alleged unlawful advertising of medicinal cannabis products.
The company allegedly promoted the use of unapproved prescription-only medicinal cannabis products, including their own products.
Businesses can only advertise prescription-only medicines exclusively to health professionals and not to the public.
The TGA facilitates legal pathways for doctors to prescribe medicinal cannabis products to patients. Advertising of prescription-only medicines directly to consumers undermines the doctor-patient relationship and may create an inappropriate demand for medicines which may not be right for the individual.
Ensuring compliance with the import, advertising and supply requirements of the Therapeutic Goods Act in relation to medicinal cannabis is a priority for the TGA. We will continue to investigate and take action in relation to alleged non-compliant advertising of medicinal cannabis products to the public. The TGA has published several medicinal cannabis resources for consumers, health professionals and businesses.
If you suspect non-compliance in relation to therapeutic goods, you can report illegal or questionable practices and report suspected non-compliant advertising on the TGA website.
Contact for members of the media:
- Email: news@health.gov.au
- Phone: 02 6289 7400